Medical Fair Asia

Global Hospital & Healthcare Management

 

 

 

Friday
May 26th
  • Bookmark and Share
  • Login
  • Sign up
    Registration
    Fields marked with an asterisk (*) are required.
    Name: *
    Username: *
    E-mail: *
    Password: *
    Verify Password: *
    Company name: *
    Position:
    Telephone:
  • Search
Text size
  • Increase font size
  • Default font size
  • Decrease font size
Home arrow Knowledge Bank arrow News arrow Perrigo Signs Agreement To Divest Tysabri Royalty Stream For Up To 2 billion dollars
Perrigo Signs Agreement To Divest Tysabri Royalty Stream For Up To 2 billion dollars
Print E-mail
Monday, 27 February 2017
Perrigo Company plc , a leading global provider of Quality Affordable Healthcare Products announced it has signed a definitive agreement to divest its rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to RPI Finance Trust, an affiliate of Royalty Pharma ("RPI").

This transaction is valued at a total consideration of up to $2.85 billion, composed of $2.2 billion in cash at closing and up to $650 million in potential milestone payments based upon future global net sales of Tysabri® in 2018 and 2020. This transaction is expected to close within 30 business days, subject to certain specified closing deliverables.
 

Perrigo's CEO John T. Hendrickson stated, "Today's announcement is the result of Perrigo's review of strategic alternatives for the Tysabri® royalty stream announced in November 2016. We are pleased to have reached an agreement that maximizes the value of this non-core asset. While dilutive to adjusted EPS, the significant upfront cash component will allow us to de-lever our balance sheet, which supports our investment grade financial policy, and better positions Perrigo to pursue our strategic plan. This transaction also furthers our stated strategy to enhance our portfolio and focus on our consumer-facing and Rx businesses. This is a meaningful step in our portfolio review process and I am confident that the Board and management will continue to focus on creating value for shareholders."

Royalty Pharma's CEO, Pablo Legorreta, stated, "We are pleased to complete this important transaction with Perrigo and help Perrigo meet its strategic objective.  Our diversified portfolio results in a low cost of capital, enabling us to provide the highest value to holders of royalties. Tysabri® is a product we have followed for many years, serving an important need in patients suffering from multiple sclerosis. We are excited to have a royalty interest in this critical therapy."

Under the terms of the agreement, Royalty Pharma will acquire all of Perrigo's rights to receive Tysabri® royalty payments from and after January 1, 2017, which Perrigo has under an agreement with Biogen, Inc.  Royalty Pharma will pay a cash purchase price of $2.2 billion at closing, plus additional payments of $250 million if the royalties earned on global net sales of Tysabri® meet specified thresholds during 2018 and $400 million if the royalties earned on global net sales of Tysabri® meet specified thresholds in 2020. Perrigo will also assign to Royalty Pharma certain information and audit rights under Perrigo's existing agreement with Biogen. The agreement provides that the transaction will close within 20 business days, subject to a 10 business day extension at Royalty Pharma's option upon Royalty Pharma's making a $1 billion purchase price deposit.   

Tysabri® is an FDA approved treatment for multiple sclerosis. Perrigo acquired the rights to the Tysabri® royalty stream through the Company's 2013 acquisition of Elan Corporation plc.

Morgan Stanley & Co. LLC acted as sole structuring agent and lead financial advisor for this transaction. Evercore also acted as financial advisor to the Company and Wachtell, Lipton, Rosen & Katz is acting as a legal advisor to Perrigo. J.P. Morgan Securities LLC and BofA Merrill Lynch acted as financial advisors, and Goodwin Procter LLP and Matheson acted as legal advisors to Royalty Pharma in connection with this transaction. 

About Perrigo
Perrigo Company plc, a leading global over-the-counter ("OTC") consumer goods company, offers patients and customers high quality products at affordable prices. From its beginning in 1887 as a packager of home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC healthcare products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products in the U.S., and receives royalties from sales of the multiple sclerosis drug, Tysabri®. Perrigo provides "Quality Affordable Healthcare Products®" across a wide variety of product categories and geographies, primarily in North America, Europe, and Australia, as well as in other markets, including Israel, China, and Latin America. Visit Perrigo online at (http://www.perrigo.com).

About Royalty Pharma
Founded in 1996, Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property, with over $15 billion in royalty assets.  Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors).  The company's portfolio includes royalty interests in over 40 approved products including AbbVie's Humira, AbbVie and J&J's Imbruvica, Biogen's Tecfidera, Vertex's Kalydeco and Orkambi, J&J's Remicade, Merck's Januvia, Gilead's Atripla and Truvada, Pfizer's Lyrica, and Astellas and Pfizer's Xtandi. Royalty Pharma is also a leading investor in pre-approval royalties, having committed over $850 million to direct R&D funding in exchange for royalties, and having invested over $4 billion in royalties on pre-approval products since 2011. 

For further information: Perrigo Contacts: 
Bradley Joseph, 
Vice President, 
Global Investor Relations & Corporate Communications, 
(269) 686-3373; 
e-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Arthur J. Shannon, 
Vice President, 
Global Corporate Affairs and European Investor Relations, 
+353 1709 4709, 
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Royalty Pharma Contact: 
Alexander v. Perfall, 
Vice President, 
Investor Relations & Public Affairs, 
(212) 883-2298, 
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
 
< Prev   Next >
Global Congress on prostate cancer
SUBSCRIPTION
Subscribe for E-Newsletter

Publication

hospital-and-healthcare-management-magazine
April 2017 - PDF | e-book

Data & Data Driven Technologies are the key elements playing important role in many aspects of the healthcare delivery system.

With this in mind, we introduce the latest edition of Hospital & Healthcare Management Magazine - Vol 6 Issue 1 your one-stop resource that hepls you stay up to date with the issues that matters the most.

View Previous Issues:
Aug'16 | May'16 | Feb'16 | Aug'15 | Feb'15 | Aug'14 | Feb'14 | June'13 | Feb.'13 | Aug.'12 | Apr.'12 | Dec.'11 | Aug.'11 | >> 

Feedback Form
Real Time Web Analytics